St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature
暂无分享,去创建一个
[1] S S Chatterjee,et al. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. , 1998, Pharmacopsychiatry.
[2] M. Groves. Hypericum perforatum L. , 1998 .
[3] S. Frokjaer,et al. High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. , 1988, Biochemical pharmacology.
[4] H. Wagner,et al. Inhibition of type A and type B monoamine oxidases by naturally occurring xanthones. , 1981, Planta medica.
[5] J. Falloon,et al. Indinavir concentrations and St John's wort , 2000, The Lancet.
[6] R. Kessler,et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. , 1998, JAMA.
[7] O. Krishtal,et al. Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. , 1999, Life sciences.
[8] P. Cowen,et al. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers , 1999, Biological Psychiatry.
[9] A. Nahrstedt,et al. Biologically Active and Other Chemical Constituents of the Herb of Hypericum perforatum L. , 1997, Pharmacopsychiatry.
[10] W. Müller,et al. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. , 1995, Arzneimittel-Forschung.
[11] E. Ernst. St. John's Wort, an anti-depressant? A systematic, criteria-based review. , 1995, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[12] J. Cott. In Vitro Receptor Binding and Enzyme Inhibition by Hypericum perforatum Extract , 1997, Pharmacopsychiatry.
[13] S. Risch,et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. , 2000, Life sciences.
[14] R. Kaufmann,et al. Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. , 1999, Photochemistry and photobiology.
[15] E. Esposito,et al. Effect of Acute Administration of Hypericum Perforatum-CO2 Extract on Dopamine and Serotonin Release in the Rat Central Nervous System , 2000, Pharmacopsychiatry.
[16] G. Bove. Acute neuropathy after exposure to sun in a patient treated with St John's Wort , 1998, The Lancet.
[17] A. Nahrstedt,et al. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. , 1998, Planta medica.
[18] Y. Öztürk. Testing the antidepressant effects of Hypericum species on animal models. , 1997 .
[19] J. Cott. Medicinal plants and dietary supplements: sources for innovative treatment or adjuncts? , 1995, Psychopharmacology bulletin.
[20] L. S. Koupparis. Harmless herbs: a cause for concern? , 2000, Anaesthesia.
[21] R. Scholten,et al. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines , 1999, Annals of Internal Medicine.
[22] N. Fineberg,et al. SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OCD , 1992, Clinical neuropharmacology.
[23] U. Hafner,et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. , 1998, Pharmacopsychiatry.
[24] W. Muller,et al. JOHANNISKRAUT : IN-VITRO-STUDIE UBER HYPERICUM-EXTRAKT, HYPERICIN UND KAMPFEROL ALS ANTIDEPRESSIVA , 1996 .
[25] Y. Oztürk. Testing the antidepressant effects of Hypericum species on animal models. , 1997, Pharmacopsychiatry.
[26] M. Ploch,et al. Modulation of Cytokine Expression by Hypericum Extract , 1994 .
[27] V. Giambanco,et al. St. John's Wort and Antidepressant Drug Interactions in the Elderly , 1999, Journal of geriatric psychiatry and neurology.
[28] A. Fugh-Berman,et al. Dietary supplements and natural products as psychotherapeutic agents. , 1999, Psychosomatic medicine.
[29] J. Brockmöller,et al. Hypericin and Pseudohypericin: Pharmacokinetics and Effects on Photosensitivity in Humans , 1997, Pharmacopsychiatry.
[30] M Kieser,et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. , 1998, Pharmacopsychiatry.
[31] J. Brockmöller,et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin , 1996, Antimicrobial agents and chemotherapy.
[32] U. Hafner,et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. , 1997, Pharmacopsychiatry.
[33] P. Cowen,et al. Antidepressant-like effect of Hypericum perforatum (St John’s wort) on the sleep polysomnogram , 1998, Psychopharmacology.
[34] J. Vry,et al. Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism , 1999, European Neuropsychopharmacology.
[35] J. Neary,et al. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes , 1999, Brain Research.
[36] J. Streltzer,et al. St. John's wort for depression: a meta-analysis of well-defined clinical trials. , 1999, The Journal of nervous and mental disease.
[37] F. Firenzuoli,et al. Effects of Hypericum perforatum on Levels of 5‐Hydroxytryptamine, Noradrenaline and Dopamine in the Cortex, Diencephalon and Brainstem of the Rat , 1999, The Journal of pharmacy and pharmacology.
[38] A. Burstein,et al. St John's Wort: Effect on CYP3A4 activity , 2000 .
[39] H M Thiede,et al. Inhibition of MAO and COMT by hypericum extracts and hypericin. , 1994, Journal of geriatric psychiatry and neurology.
[40] H. Wagner,et al. Inhibition of monoamine oxidase by hypericin. , 1984, Planta medica.
[41] D. Overstreet,et al. Attenuation of alcohol intake by extract of Hypericum perforatum (St. John's Wort) in two different strains of alcohol-preferring rats. , 1999, Alcohol and alcoholism.
[42] V. Zlotnik,et al. Neuropharmacology of St. John's Wort (Hypericum) , 1998, The Annals of pharmacotherapy.
[43] S. Okpanyi,et al. [Genotoxicity of a standardized Hypericum extract]. , 1990, Arzneimittel-Forschung.
[44] S. Mace,et al. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression , 2000, Expert opinion on pharmacotherapy.
[45] S. Chatterjee,et al. Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human Volunteers , 1998, Pharmacopsychiatry.
[46] S. Bhattacharya,et al. Hyperforin as a possible antidepressant component of hypericum extracts. , 1998, Life sciences.
[47] S. Kaehler,et al. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus , 1999, Neuroscience Letters.
[48] B. Gaster,et al. St John's wort for depression: a systematic review. , 2000, Archives of internal medicine.
[49] W. Dimpfel,et al. Pharmacodynamic Effects of two Different Hypericum Extracts in Healthy Volunteers Measured by Quantitative EEG , 1998, Pharmacopsychiatry.
[50] I. Roots,et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.
[51] H. Schulz,et al. Effects of hypericum extract on the sleep EEG in older volunteers. , 1994, Journal of geriatric psychiatry and neurology.
[52] J. Brockmöller,et al. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. , 1994, Journal of geriatric psychiatry and neurology.
[53] G. Pepeu,et al. [Monoamine oxidase inhibitors in the aged]. , 1964, Giornale di gerontologia. Supplemento.
[54] W. Müller,et al. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. , 1999, The Journal of pharmacology and experimental therapeutics.
[55] C. Erdelmeier. Hyperforin, Possibly the Major Non-Nitrogenous Secondary Metabolite of Hypericum perforatum L. , 1998, Pharmacopsychiatry.
[56] M. Nöldner,et al. Antidepressant Activity of Hypericum Perforatum and Hyperforin: the Neglected Possibility , 1998, Pharmacopsychiatry.
[57] C. Mulrow,et al. St John's wort for depression—an overview and meta-analysis of randomised clinical trials , 1996, BMJ.
[58] H. Schulz,et al. Memory self-report in Alzheimer's disease and in age-associated memory impairment. , 1994 .
[59] E. Elstner,et al. Biochemical Activities of Extracts from Hypericum perforatum L. 1st Communication: Inhibition of dopamine - β - hydroxylase , 1999, Arzneimittelforschung.
[60] J. Deltito,et al. The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. , 1998, Journal of affective disorders.
[61] W. Burkard,et al. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. , 1997, Pharmaceutica acta Helvetiae.
[62] H. Wagner,et al. Inhibition of MAO by Fractions and Constituents of Hypericum Extract , 1994 .
[63] E. Ernst,et al. Second thoughts about safety of St John's wort , 1999, The Lancet.
[64] H. Wagner,et al. Pharmaceutical Quality of Hypericum Extracts , 1994, Journal of geriatric psychiatry and neurology.
[65] C. Miranda,et al. Consumption of poisonous plants (Senecio jacobaea, Symphytum officinale, Pteridium aquilinum, Hypericum perforatum) by rats: chronic toxicity, mineral metabolism, and hepatic drug-metabolizing enzymes. , 1982, Toxicology letters.
[66] A. Nierenberg,et al. Mania associated with St. John’s wort , 1999, Biological Psychiatry.
[67] G. Harrer,et al. Comparison of Equivalence between the St. John’s Wort Extract LoHyp-57 and Fluoxetine , 1999, Arzneimittelforschung.
[68] R. Valentino,et al. Pharmacology of locus coeruleus spontaneous and sensory-evoked activity. , 1991, Progress in brain research.
[69] J. Vetulani,et al. Mode of action of antidepressant drugs. , 1978, Biochemical pharmacology.
[70] John A. Astin. Why Patients Use Alternative Medicine: Results of a National Study , 1999 .
[71] J. Yager,et al. Use of alternative remedies by psychiatric patients: illustrative vignettes and a discussion of the issues. , 1999, The American journal of psychiatry.
[72] E. Ernst,et al. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.) , 1998, European Journal of Clinical Pharmacology.
[73] S H Snyder,et al. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. , 1980, Science.
[74] J. Pepping. St. John's wort: Hypericum perforatum. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[75] J. Gleitz,et al. Effects of Long-Term Administration of Hypericum Extracts on the Affinity and Density of the Central Serotonergic 5-HT1 A and 5-HT2 A Receptors , 1997, Pharmacopsychiatry.
[76] M. Gobbi,et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[77] Cott Jm. Medicinal plants and dietary supplements: sources for innovative treatment or adjuncts? , 1995 .
[78] J. Simon,et al. Hypericin Levels in Human Serum and Interstitial Skin Blister Fluid after Oral Single-Dose and Steady-State Administration of Hypericum perforatum Extract (St. John’s Wort) , 1999, Skin Pharmacology and Physiology.
[79] W. Dimpfel,et al. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG). , 1998, Pharmacopsychiatry.
[80] R. Ciccocioppo,et al. Effects of Hypericum perforatum extraction on alcohol intake in Marchigian Sardinian alcohol-preferring rats. , 1999, Alcohol and alcoholism.
[81] A. Nahrstedt,et al. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. , 1997, Pharmacopsychiatry.
[82] W. Dimpfel,et al. Central action of hyperici herba cum flore extractum siccum in freely moving rats. , 1997, European Journal of Medical Research.
[83] A. Holtz,et al. Fluoxetine tenth anniversary update: the progress continues. , 1997, Clinical therapeutics.
[84] H. Woelk,et al. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. , 1994, Journal of geriatric psychiatry and neurology.
[85] L. Cohen,et al. St John's wort during pregnancy. , 1998, JAMA.
[86] Dr. Peter H. Yu. Effect of the Hypericum Perforatum Extract on Serotonin Turnover in the Mouse Brain , 2000, Pharmacopsychiatry.
[87] S. Priebe,et al. Assessing the quality of psychiatric hospital care: a German approach. , 1998, Psychiatric services.
[88] S. Ettner,et al. Trends in alternative medicine use in the United States , 1999 .
[89] R. Raffa. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. , 1998, Life sciences.
[90] C. Gambarana,et al. Efficacy of an Hypericum Perforatum (St. John's Wort) Extract in Preventing and Reverting a Condition of Escape Deficit in Rats , 1999, Neuropsychopharmacology.
[91] J. Tuomisto,et al. Neurotransmitter regulation of anterior pituitary hormones. , 1985, Pharmacological reviews.